title: High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma.
authors.forename: Massimo
authors.initials: M
authors.lastname: Magagnoli
authors.forename: Monica
authors.initials: M
authors.lastname: Balzarotti
authors.forename: Licia Vanessa
authors.initials: LV
authors.lastname: Siracusano
authors.forename: Michele
authors.initials: M
authors.lastname: Spina
authors.forename: Luciano
authors.initials: L
authors.lastname: Isa
authors.forename: Emanuela
authors.initials: E
authors.lastname: Morenghi
authors.forename: Umberto
authors.initials: U
authors.lastname: Tirelli
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012008:Recurrence
chemical_list: D001761:Bleomycin; D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide; D011241:Prednisone